Loading...
Loading...
India's meropenem imports from SWITZERLAND total $418.3M across 57 shipments from 3 foreign suppliers. PFIZER SERVICE COMPANY BV leads with $417.5M in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include PFIZER LIMITED. This corridor reflects India's pharmaceutical import demand for meropenem โ a concentrated sourcing relationship with select suppliers from SWITZERLAND.

PFIZER SERVICE COMPANY BV is the leading Meropenem supplier from SWITZERLAND to India, with import value of $417.5M across 54 shipments. The top 5 suppliers โ PFIZER SERVICE COMPANY BV, PFIZER SERVICE COMPANY BVBA, OXIMIO HUNGARY KFT. โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PFIZER SERVICE COMPANY BV | $417.5M | 54 | 99.8% |
| 2 | PFIZER SERVICE COMPANY BVBA | $832.3K | 2 | 0.2% |
| 3 | OXIMIO HUNGARY KFT. | $369 | 1 | 0.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PFIZER LIMITED | $418.3M | 56 | 100.0% |
| 2 | WOCKHARDT LIMITED | $369 | 1 | 0.0% |
SWITZERLAND โ India trade corridor intelligence
As of April 2026, the Switzerland to India trade corridor for pharmaceutical imports is operating efficiently. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are handling shipments without significant congestion. Freight rates have stabilized, and the exchange rate between the Swiss Franc and the Indian Rupee remains favorable for importers.
The Indian government's PLI scheme aims to boost domestic manufacturing and reduce import dependency. While this may impact the volume of imported Meropenem formulations, the demand for high-quality products ensures that imports from countries like Switzerland continue to play a vital role in the Indian market.
India and Switzerland maintain strong trade relations, with ongoing negotiations to enhance bilateral agreements and mutual recognition of Good Manufacturing Practices (GMP). These efforts aim to streamline trade processes and facilitate the import of pharmaceutical formulations, including Meropenem, ensuring compliance with both countries' standards.
The landed cost of importing Meropenem formulations from Switzerland to India includes the Free on Board (FOB) price, freight charges, insurance, Basic Customs Duty (BCD) of 10%, Social Welfare Surcharge (SWS) of 10%, Integrated Goods and Services Tax (IGST) of 12%, port handling charges, and Customs House Agent (CHA) fees. The total landed duty is approximately 17.10%. Per-unit estimates depend on the specific product and shipment details.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Meropenem into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each batch of the formulation must be registered with the CDSCO, which involves submitting Form CT-20/40/41, along with the necessary documentation, including a Certificate of Pharmaceutical Product (CoPP), Certificate of Analysis (CoA), and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the workload of the CDSCO. Meropenem formulations under HS Code 30049099 are subject to these registration requirements.
Imported Meropenem formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a CoA, confirming compliance with the Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to ensure the product's efficacy and safety under Indian climatic conditions. Port inspections by customs drug inspectors are mandatory to verify the authenticity and quality of the imported formulations.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical formulations, including Meropenem. The introduction of the Production Linked Incentive (PLI) scheme has encouraged domestic manufacturing, potentially affecting the volume of imported formulations. Bilateral agreements between India and Switzerland have facilitated smoother trade processes, but importers must stay updated on any policy changes that may impact import procedures.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 17.10%
India imports finished Meropenem formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for Meropenem formulations is limited, leading to a reliance on imports to fulfill market needs. The Indian market for Meropenem formulations is substantial, with a growing demand due to the increasing incidence of infections requiring such treatments.
The import duty structure for Meropenem formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The Social Welfare Surcharge (SWS) is 10%. The Integrated Goods and Services Tax (IGST) is 12%. There are no exemptions or concessional rates for imports from Switzerland. The total landed duty is approximately 17.10%.
India sources Meropenem formulations from Switzerland due to the high quality and reliability of Swiss pharmaceutical products. Swiss manufacturers offer patented formulations and specialized dosage forms that are not available from other suppliers. While other countries like China, Germany, and the US also supply Meropenem formulations, Switzerland's reputation for quality and innovation gives it a competitive edge in the Indian market.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Meropenem formulations from Switzerland due to the availability of patented formulations, specialized dosage forms, and technology-licensed products. Swiss manufacturers provide specific formulations that are not produced domestically, fulfilling a critical need in the Indian market.
Compared to other origins like China, the European Union, and the United States, Switzerland offers superior quality, regulatory compliance, and reliability in the supply of Meropenem formulations. While other countries may offer lower prices, Switzerland's unique advantage lies in its consistent product quality and adherence to international standards.
Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to global supply chain issues, highlighting the need for strategic sourcing and risk management.
Import license checklist, document requirements, quality testing, and compliance
Upon arrival, customs drug inspectors collect samples of each batch of Meropenem formulations for testing at CDSCO-approved laboratories. The testing process includes verifying compliance with the Indian Pharmacopoeia standards and assessing the stability data. If a batch fails to meet the required standards, it may be rejected, and the importer could face penalties. Common quality issues from Swiss imports are rare but can include discrepancies in labeling or packaging.
Importers must renew their CDSCO registration annually and comply with periodic audits in Switzerland to ensure continued adherence to Good Manufacturing Practices (GMP). Change control procedures must be in place to manage any modifications in the formulation or manufacturing process. Pharmacovigilance systems should be established for post-import monitoring of adverse events. Import records must be maintained as per the Drug and Cosmetics Act for regulatory compliance.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Meropenem suppliers from SWITZERLAND to India include PFIZER SERVICE COMPANY BV, PFIZER SERVICE COMPANY BVBA, OXIMIO HUNGARY KFT.. The leading supplier is PFIZER SERVICE COMPANY BV with import value of $417.5M USD across 54 shipments. India imported Meropenem worth $418.3M USD from SWITZERLAND in total across 57 shipments.
India imported Meropenem worth $418.3M USD from SWITZERLAND across 57 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Meropenem sourced from SWITZERLAND include PFIZER LIMITED, WOCKHARDT LIMITED. The largest buyer is PFIZER LIMITED with $418.3M in imports across 56 shipments.
The total value of Meropenem imports from SWITZERLAND to India is $418.3M USD, across 57 shipments and 3 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
57 Verified Shipments
3 suppliers, 2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists